Navigation Links
Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
Date:11/7/2007

SAN FRANCISCO, Nov. 7 /PRNewswire/ -- Epiphany Biosciences announced today that the first patient was enrolled in a Phase 2b clinical trial with valomaciclovir (EPB-348) for the treatment of herpes zoster, also known as shingles. Valomaciclovir is a highly potent anti-viral with enhanced delivery and bioavailability.

"The initiation of this dose-finding study is an important milestone in our development of valomaciclovir," said Fred Volinsky, MD, Chief Executive Officer. "Shingles, especially in the elderly population, can pose a serious threat to quality of life. Despite the approval of the adult zoster vaccine, we believe that the potential market for effective zoster medications will double in size based on the published vaccine efficacy rates and the aging of the baby boomers."

"There are roughly one million cases of herpes zoster in the United States annually and current therapy requires multiple dosing, anywhere from three to five times a day. These dosing schedules can be problematic for patient populations who are already taking multiple medications for other co-morbid conditions," stated Brian Murphy, MD, Chief Medical Officer. "This clinical trial is designed to examine the safety and efficacy of once-daily valomaciclovir against an active comparator, three times daily valacyclovir, and is adequately powered to assess a number of pivotal outcomes."

"Advancing a therapy that is conducive to better compliance is sorely needed in this therapeutic space," noted Dr. Stephen Tyring, Professor of Medicine at the University of Texas Health Science Center in Houston and principal investigator for the study. "In light of the improved pharmacodynamic profile offered by this drug, it is important to study it in larger, diverse populations that can be affected by herpes zoster."

The number of elderly patients at-risk for this disease is expected to increase dramatically over the next decade as the world population ages. "While we are working to advance valomaciclovir to become the next global brand for the management of shingles, we are pleased that this compound also exhibits activity both in vitro and in vivo against other types of viruses. We plan to explore these potential broad therapeutic possibilities given the spectrum of this anti-viral profile," said Dr. Volinsky.

About Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for viral disease. Epiphany has formed a world-class virology team that includes two Lasker Award winners. Epiphany is located in San Francisco, CA. Additional information on Epiphany Biosciences may be obtained at the company website, http://www.epiphanybio.com, or by contacting company representatives at 415.765.7193.


'/>"/>
SOURCE Epiphany Biosciences
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... -- Research and Markets has announced ... Applications, Technologies, Forecasts" report to their offering. ... Smart Skin, Structural Health Monitoring, Composite Smart Structures, ... involves electronic and/or electrical components and circuits that ... such as vehicle bodies or conformally placed upon ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... Birmingham, Lake Orion, Clarkston, Michigan (PRWEB) , ... ... ... their direction with respect to fertility once they have been diagnosed with endometriosis. ... for tolerable intercourse but they also require a comprehensive approach that can help ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):